BACKGROUND Cost-effectiveness of Psychotherapy for Cluster C Personality Disorders and the Value of Information and Implementation Djøra I. Soeteman 1,2,

Slides:



Advertisements
Similar presentations
Acknowledgements RHH ED staff Safety and Quality Unit RHH for their participation and valuable contribution Next Steps It is envisaged over the next 12.
Advertisements

When is there Sufficient Evidence? Karl Claxton, Department of Economics and Related Studies and Centre for Health Economics, University of York.
Markov Models: Overview Gerald F. Kominski, Ph.D. Professor, Department of Health Services.
1 Are you sure your improvements are cost-effective? Edward Broughton, PhD, MPH, PT University Research Co. April 11, 2014
Cost-Effectiveness Using Decision-Analytic Models
Copyright © 2002 by The McGraw-Hill Companies, Inc. All rights reserved. McGraw-Hill/Irwin Chapter Twenty An Introduction to Decision Making GOALS.
Exploring uncertainty in cost effectiveness analysis NICE International and HITAP copyright © 2013 Francis Ruiz NICE International (acknowledgements to:
1 Value of Information Yot Teerawattananon, MD International Health Policy Program, Ministry of Public Health PhD candidate in Health Economics, University.
Optimal Drug Development Programs and Efficient Licensing and Reimbursement Regimens Neil Hawkins Karl Claxton CENTRE FOR HEALTH ECONOMICS.
1 A Health Economic View on Borderline Personality Disorder Prof. dr. Jan Busschbach Viersprong Institute for studies on Personality Disorders Medical.
Valuing Trial Designs from a Pharmaceutical Perspective using Value Based Pricing (VBP) Penny Watson 1, Alan Brennan 1 1 Health Economics and Decision.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Prof. dr. Jan van Busschbach Department of Medical Psychology & Psychotherapy Erasmus MC.
1 Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
The Importance of Decision Analytic Modelling in Evaluating Health Care Interventions Mark Sculpher Professor of Health Economics Centre for Health Economics.
Cost-Effectiveness Analyses in the UK - Lessons from the National Institute for Clinical Excellence Mark Sculpher Professor of Health Economics Centre.
The Cost-Effectiveness and Value of Information Associated with Biologic Drugs for the Treatment of Psoriatic Arthritis Y Bravo Vergel, N Hawkins, C Asseburg,
Results 2 (cont’d) c) Long term observational data on the duration of effective response Observational data on n=50 has EVSI = £867 d) Collect data on.
Prioritising HTA funding: The benefits and challenges of using value of information in anger CENTRE FOR HEALTH ECONOMICS K Claxton, L Ginnelly, MJ Sculpher,
Making Cost Effectiveness Analyses more useful: Budget Impact Curves Christopher McCabe PhD Endowed Research Chair in Emergency Medicine Research University.
Decision Analysis as a Basis for Estimating Cost- Effectiveness: The Experience of the National Institute for Health and Clinical Excellence in the UK.
Health Economics & Policy 3 rd Edition James W. Henderson Chapter 4 Economic Evaluation in Health Care.
Value of Information Calculations to Inform and Prioritize Clinical Research Investments David Meltzer MD, PhD The University of Chicago.
1 Cost-effectiveness in Personality Disorder Dr. J.J.V. Busschbach Psychotherapeutic centre ‘De Viersprong’ –PO Box AA Halsteren
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 16: Economic Evaluation using Decision.
1 Cost-effectiveness of improving medical services in low-resource settings Edward Broughton, PhD, MPH, PT University Research Co. May 21, 2014
Back to Basics: Health Economics Gavin Lewis, Head of Health Economics, Roche BOPA, Brighton, 18 th October, 2009 HCMR00008 / Date of Preparation October.
Evidence Evaluation & Methods Workgroup: Developing a Decision Analysis Model Lisa A. Prosser, PhD, MS September 23, 2011.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 17: Economic Evaluation using Decision.
Background to Adaptive Design Nigel Stallard Professor of Medical Statistics Director of Health Sciences Research Institute Warwick Medical School
Cost-Effectiveness of Palliative Team Care For Patients Nearing End-Of-Life Society for Medical Decision Making 36 st Annual Meeting – Miami, Florida October.
Cost-effectiveness of psychotherapy for personality disorders Djøra Soeteman Viersprong Institute for Studies on Personality Disorders Erasmus Medical.
Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D Viersprong Institute for studies on Personality Disorders (VISPD)
1 Cost effectiveness as argument for reimbursement in prevention Jan J. v. Busschbach, Ph.D. Erasmus MC –Institute for Medical Psychology and Psychotherapy.
Economic evaluation of psychotherapy for personality disorders: burden of disease and cost-effectiveness Djøra Soeteman Viersprong Institute for Studies.
1 The Economic Burden of Personality Disorders  Djøra Soeteman, Jan J.V. Busschbach, Leona Hakkaart-van Roijen, Roel Verheul  Viersprong Institute for.
Costs of Neurostimulation Can We Afford The Therapy in 2020? Krishna Kumar MBBS MS FRCS(C) Member Ord. of Canada, Saskatchewan Ord. of Merit Clinical Professor.
HEALTH ECONOMICS/PHARMACOECONOMICS FOR NON- HEALTH ECONOMISTS INTRODUCTION Elhem Sbaa Keyrus Biopharma.
Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy Viersprong.
11 Cost Effectiveness in Preventing Crime  Jan van Busschbach, Djøra Soeteman  Viersprong Institute for studies on Personality Disorders VISPD  Erasmus.
Treatment selection in patients with personality disorders: The role of patient characteristics Helene Andrea Janine van Manen, Anna Bartak, Jan van Busschbach,
1 The Cost Effectiveness of Treatment of Personality Disorder  Dr. Jan J.V. Busschbach  PTC De Viersprong, Erasmus MC, Rotterdam, 
Cost-Effectiveness of Psychotherapy for Personality Disorders Soeteman, Busschbach, Verheul.
Cost-effectiveness in the quest to convince the outside world Dr. Jan Busschbach De Viersprong Erasmus MC
1 Interactive Introduction Cost Effectiveness and Psychotherapy Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
1 The Economics of Health Care and New Technologies Friday October 18, 2002 Between Technology and Humanity, Brussels Jan Busschbach PhD, –Department of.
1 Value of Information in relation to risk management  Prof. Dr. Jan J.V. Busschbach.
The Role of Perspective in Economic Evaluation for Cancer Prevention Steven Kymes, Ph.D. Research Associate Professor of Ophthalmology And Visual Sciences.
Cost-Effectiveness of Psychotherapy (for Personality Disorders) Prof. dr. Jan van Busschbach.
Conceptual Addition of Adherence to a Markov Model In the adherence-naïve model, medication adherence and associated effectiveness assumed to be trial.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
● The results of this study suggest that using the prognostic test to guide ACT decisions in NSCLC is cost-effective compared to a SoC approach according.
CT Screening for Lung Cancer vs. Smoking Cessation: A Cost-Effectiveness Analysis Pamela M. McMahon, PhD; Chung Yin Kong, PhD; Bruce E. Johnson; Milton.
Date of download: 6/1/2016 From: Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus Ann Intern Med. 2015;162(6): doi: /M
Date of download: 6/2/2016 From: New Protease Inhibitors for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Ann Intern Med. 2012;156(4):
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
1 Edward Broughton, PhD., MPH Director of Research and Evaluation, USAID Health Care Improvement Project, University Research Co., LLC
Economics of Complementary and Integrative Medicine: Where Do We Go From Here? Patricia M. Herman, ND, PhD, RAND Corporation IM4US Boston August 8, 2014.
PRAGMATIC Study Designs: Elderly Cancer Trials
The University of Sheffield Extrapolation methods:
Introduction Out-of-hospital cardiac arrest (OHCA) is the sudden cessation of the heart in an out of hospital setting. In the United States, the incidence.
Cost effectiveness Analysis: Valuing Health; Valuing Research!
HEALTH ECONOMICS BASICS
Jan B. Pietzsch1, Benjamin P. Geisler1, Murray D. Esler 2
For a copy of the poster:
Secondary logo Secondary logo
Cost Effective Studies
Mechanical thrombectomy
How should we test for pre-term labour
Justification treatment cost
Presentation transcript:

BACKGROUND Cost-effectiveness of Psychotherapy for Cluster C Personality Disorders and the Value of Information and Implementation Djøra I. Soeteman 1,2, MA, Jan J. van Busschbach 1,2, PhD, Roel Verheul 1, PhD, Jane J. Kim 3, PhD 1 Viersprong Institute for Studies on Personality Disorders, Halsteren, 2 Dept. of Medical Psychology and Psychotherapy, Erasmus MC, Rotterdam, The Netherlands, 3 Center for Health Decision Science, Harvard School of Public Health, Boston, MA METHODS OBJECTIVES MODEL STRUCTURE  There are three questions which any health care system needs to address in order to improve the efficiency of health- care provision: 1). Which treatments are cost-effective and should be adopted? (reimbursement decision); 2). Is it worthwhile to conduct additional research (research decision); 3). Is it cost-effective to implement treatments into clinical practice (implementation decision). REIMBURSEMENT DECISION We acknowledge the contributions of the participating specialist centers of psychotherapy in The Netherlands: Center of Psychotherapy De Gelderse Roos, Lunteren; Medical Center Zaandam; Altrecht, Utrecht; Center of Psychotherapy Arkin, Amsterdam; GGZWNB, Bergen op Zoom; Center of Psychotherapy De Viersprong, Halsteren. IMPLEMENTATION DECISION  To evaluate the cost-effectiveness of five dosages of psychotherapy in treating avoidant, dependent, and obsessive-compulsive (i.e., cluster C) personality disorders (PD).  To assess the societal value of additional research and to identify the model parameters for which reduction of uncertainty would be most valuable.  To estimate the societal benefit associated with changing the capacity of and adherence to cost-effective treatment strategies.  Using patient-level primary data (n=466) from the largest existing clinical trial of psychotherapy for PD (i.e., SCEPTRE), we developed a probabilistic Markov cohort model.  This study compares dosage, specified by a combination of treatment setting (outpatient, day hospital, and inpatient) and duration (short-term or up to six months versus long-term or more than six months).  The analytic time horizon was five years, modeled as six- month time cycles.  Value of information and value of implementation analyses were conducted to evaluate the parameters that were responsible for most of the decision uncertainty, and to calculate the expected values of perfect information (EVPI) and perfect implementation (EVPIM). RESEARCH DECISION CONCLUSIONS  Based on a threshold value of €40,000 per QALY, short-term inpatient psychotherapy was identified as the most cost-effective treatment option.  The societal value of additional research on treatments for cluster C PD is substantial, especially when prioritizing information on treatment costs and transition probabilities.  Implementing this cost-effective treatment strategy into clinical practice is likely to improve the efficiency of health-care provision in The Netherlands.  The underlying clinical process driving the model and by which the health states are defined is ‘clinically significant change’, based on a statistical approach to defining meaningful change in psychotherapy research.  Transition probabilities were adjusted for selection bias with the multiple propensity score method.  The population expected value of perfect information (EVPI) is €587 million assuming a five-year lifetime for psychotherapy (€5,884 for individual patients).  The expected value of perfect implementation (EVPIM), based on the current level of information, was €4,381 million for the eligible population (€43,915 for individual patients).  The population expected value of partial perfect information (EVPPI) for the four groups of parameters at a cost-effectiveness threshold of €40,000 per QALY and a five-year lifetime for psychotherapy shows relatively high values associated with transition probabilities and treatment costs. REIMBURSEMENT DECISION  The cost-effectiveness acceptability frontier (CEAF) displays the switch point, at which there is a change in the optimal option from short-term day hospital psychotherapy to short-term inpatient psychotherapy (€16,570 per QALY).  The table summarizes the model projections of costs and effects of the five alternative treatment dosages of psychotherapy for cluster C PD, and highlights the most cost-effective choice (i.e., the option with the highest incremental cost-effectiveness ratio (ICER) below the threshold, or the option that maximizes net monetary benefit) at a willingness-to-pay threshold of € 40,000 per QALY.